113 related articles for article (PubMed ID: 17986862)
21. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
[TBL] [Abstract][Full Text] [Related]
22. Tumour-derived IL-10 within tumour microenvironment represses the antitumour immunity of Socs1-silenced and sustained antigen expressing DCs.
Song S; Wang Y; Wang J; Lian W; Liu S; Zhang Z; Liu F; Wei L
Eur J Cancer; 2012 Sep; 48(14):2252-9. PubMed ID: 22230748
[TBL] [Abstract][Full Text] [Related]
23. Dendritic cells pulsed with placental gp96 promote tumor-reactive immune responses.
Zheng H; Liu L; Zhang H; Kan F; Wang S; Li Y; Tian H; Meng S
PLoS One; 2019; 14(1):e0211490. PubMed ID: 30703157
[TBL] [Abstract][Full Text] [Related]
24. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
[TBL] [Abstract][Full Text] [Related]
25. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response.
Ji Q; Gondek D; Hurwitz AA
J Immunol; 2005 Aug; 175(3):1456-63. PubMed ID: 16034082
[TBL] [Abstract][Full Text] [Related]
26. Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model.
Kollessery G; Nordgren TM; Mittal AK; Joshi SS; Sanderson SD
Vaccine; 2011 Aug; 29(35):5904-10. PubMed ID: 21723901
[TBL] [Abstract][Full Text] [Related]
27. Efficient nonviral transfection of dendritic cells and their use for in vivo immunization.
Irvine AS; Trinder PK; Laughton DL; Ketteringham H; McDermott RH; Reid SC; Haines AM; Amir A; Husain R; Doshi R; Young LS; Mountain A
Nat Biotechnol; 2000 Dec; 18(12):1273-8. PubMed ID: 11101806
[TBL] [Abstract][Full Text] [Related]
28. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
29. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
[TBL] [Abstract][Full Text] [Related]
30. Combination vaccine of dendritic cells (DCs) and T cells effectively suppressed preestablished malignant melanoma in mice.
Asada H; Kishida T; Hirai H; Shin-Ya M; Imanishi J; Takeuchi M; Mazda O
Cancer Lett; 2006 Aug; 240(1):83-93. PubMed ID: 16246489
[TBL] [Abstract][Full Text] [Related]
31. Shift from systemic to site-specific memory by tumor-targeted IL-2.
Schrama D; Xiang R; Eggert AO; Andersen MH; Pedersen Ls LØ; Kämpgen E; Schumacher TN; Reisfeld RR; Becker JC
J Immunol; 2004 May; 172(10):5843-50. PubMed ID: 15128763
[TBL] [Abstract][Full Text] [Related]
32. Gene transfer to dendritic cells induced a protective immunity against melanoma.
Metharom P; Ellem KA; Wei MQ
Cell Mol Immunol; 2005 Aug; 2(4):281-8. PubMed ID: 16274626
[TBL] [Abstract][Full Text] [Related]
33. Whole blood cells loaded with messenger RNA as an anti-tumor vaccine.
Phua KK; Boczkowski D; Dannull J; Pruitt S; Leong KW; Nair SK
Adv Healthc Mater; 2014 Jun; 3(6):837-42. PubMed ID: 24339387
[TBL] [Abstract][Full Text] [Related]
34. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
[TBL] [Abstract][Full Text] [Related]
35. Vaccination with dendritic cells charged with apoptotic/necrotic B16 melanoma induces the formation of subcutaneous lymphoid tissue.
Mac Keon S; Gazzaniga S; Mallerman J; Bravo AI; Mordoh J; Wainstok R
Vaccine; 2010 Nov; 28(51):8162-8. PubMed ID: 20937314
[TBL] [Abstract][Full Text] [Related]
36. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
37. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model.
Grauer OM; Sutmuller RP; van Maren W; Jacobs JF; Bennink E; Toonen LW; Nierkens S; Adema GJ
Int J Cancer; 2008 Apr; 122(8):1794-802. PubMed ID: 18076066
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant.
Yamano T; Kaneda Y; Huang S; Hiramatsu SH; Hoon DS
Mol Ther; 2006 Jan; 13(1):194-202. PubMed ID: 16112911
[TBL] [Abstract][Full Text] [Related]
39. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
40. Vaccines using dendritic cells, differentiated with propofol, enhance antitumor immunity in mice.
Inada T; Kubo K; Shingu K
Immunopharmacol Immunotoxicol; 2009; 31(1):150-7. PubMed ID: 19951075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]